Decoding the Hype and Fear of Nanomedicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Decoding the Hype and Fear of Nanomedicines
Does nanotechnology offer a cure-all or a kill all? We speak with Ruth Duncan about the real potential of nanomedicines.


Pharmaceutical Technology Europe
Volume 24, Issue 2

Q: What key factors are necessary to develop practical, safe and effective nanomedicines?

As with any medicine, an understanding of the critical product attributes that govern safety and efficacy is vitally important, as well as the ability to ensure characterisation of these parameters using validated analytical techniques. With nanomedicines, it is also important to consider the route of administration, dose, frequency of administration, fate of the nanomaterial (all components from the product), any detrimental bioactivity, antigenicity, immunogenicity and haematocompatibility.

As nano-sized medicines often display very different pharmacokinetics and body distribution compared with low-molecular chemical entities at the whole body and cellular level, the pharmacokinetics–pharmacodynamics relationship needs to be carefully considered during the establishment of critical product attributes relating to safety and efficacy. For each product, it is also essential to consider the proposed clinical setting for use.

Ruth Duncan is Professor Emerita at Cardiff University (UK), and visiting professor at CIPF (Spain) and the University of Greenwich (UK).

References

1. R. Duncan and R. Gaspar, "Nanomedicine(s) under the microscope", Mol. Pharmaceutics online, DOI: 10.1021/mp200394t, 5 Oct., 2011.

2. B. Munos, Nat. Rev. Drug Discov., 8(12), 959–968 (2009).

3. R.A. Petros and J.M. DeSimone, Rev. Drug Discov., 9(8), 615–627 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here